Vivani Medical Inc. (VANI)

In November 2025, Vivani Medical's stock decreased after a business update and Q3 financial results. In January 2026, stock offerings caused price fluctuations, Cortigent presented positive study results, and Director Gregg Williams purchased shares. In March 2026, Q4 and full-year 2025 results and NPM-139 progress led to a stock decrease, and Gregg Williams bought more shares. In April 2026, Gregg Williams continued buying shares, H.C. Wainwright lowered the price target, while another report increased it.

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company with products still in development, so there is no established demand seasonality for its products and services. The available information on "VANI Seasonality" refers to monthly stock returns rather than product demand.

Vivani Medical operates in the Healthcare sector, focusing on Biotechnology, Pharmaceuticals, and Medical Devices & Instruments. The company is developing GLP-1 based implants for metabolic diseases, including obesity, chronic weight management, and type 2 diabetes. Key products include NPM-115 for chronic weight management, NPM-119 for type 2 diabetes, NPM-139 for chronic weight management with potential for once-yearly dosing, and OKV-119 for metabolic diseases in companion animals. The company also has a neuromodulation division, Cortigent, developing implantable visual prostheses.

Vivani Medical, Inc. is headquartered in Alameda, California, United States.

Vivani Medical's brand reputation is influenced by its progress as a clinical-stage biopharmaceutical company. Positive developments like the LIBERATE-1 study and NPM-139 data enhance its scientific reputation. However, its pre-revenue status and cash burn lead to a perception as a "high-risk momentum play," with equity dilution risks affecting its reputation among some investors. Insider buying activity, particularly by Director Gregg Williams, could be interpreted as a sign of confidence in the company's direction.

Vivani Medical's ownership includes institutional, insider, and public investors. Insiders hold approximately 46.40% of the stock, with individual insiders owning the largest share at 48%. Gregg Williams owns the most shares among insiders, holding 41% of shares outstanding. Institutional investors hold approximately 6.78% of the stock, with major holders including Vanguard Group Inc., Tudor Investment Corp Et Al, and BlackRock, Inc.